Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 3/20 | 0.44 |
| ▸ | ESRRB | O95718 | 2/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940712 | 0.85 | GRIA4 (0.45) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL6948293 | 0.85 | GRIA4 (0.45) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL14839515 | 0.81 | ADRB2 (0.44) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL9848370 | 0.79 | KCNH2 (0.42) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL6990008 | 0.79 | GRIA4 (0.44) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL11075160 | 0.79 | KCNH2 (0.46) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL9848367 | 0.79 | KCNH2 (0.42) | GRIA4KCNH2TP53TSHRESRRG | |
| SCHEMBL8679307 | 0.79 | TSHR (0.58) | GRIA4KCNH2TP53TSHRRECQL | |
| SCHEMBL18253225 | 0.79 | TSHR (0.58) | GRIA4KCNH2TP53TSHRRECQL | |
| SCHEMBL14839625 | 0.79 | ADRB2 (0.43) | GRIA4KCNH2TP53TSHRESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490993-A2 | METHOD FOR PRODUCING M-SUBSTITUTED PHENYLALKANOLS BY MEANS OF ISOMERIZATION | BASF SE (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048068-A2 | METHOD FOR PRODUCING M-SUBSTITUTED PHENYLALKANOLS BY MEANS OF ISOMERIZATION | BASF SE (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-20050287232-A1 | Skin immune function controlling agents | HOSOI JUNICHI | 2005-12-29 | — | — | US | disclosed |
| US-20050119156-A1 | Aromachemicals | FLEXITRAL, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050287232-A1 | Skin immune function controlling agents | TRPA1, CD69, CUTA | GRIA4 792/4885KCNH2 808/4885TP53 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.